BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3081640)

  • 1. Regulation of human natural killer cell activity by interferon-gamma: lack of a role in interleukin 2-mediated augmentation.
    Sayers TJ; Mason AT; Ortaldo JR
    J Immunol; 1986 Mar; 136(6):2176-80. PubMed ID: 3081640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
    Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
    J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
    Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
    J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of recombinant human interferon-gamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development.
    Ueno Y; Miyawaki T; Seki H; Matsuda A; Taga K; Sato H; Taniguchi N
    J Immunol; 1985 Jul; 135(1):180-4. PubMed ID: 3923100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of in vitro porcine natural killer cell activity by recombinant interleukin-1 alpha, interleukin-2 and interleukin-4.
    Knoblock KF; Canning PC
    Immunology; 1992 Jun; 76(2):299-304. PubMed ID: 1634252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2.
    Svedersky LP; Shepard HM; Spencer SA; Shalaby MR; Palladino MA
    J Immunol; 1984 Aug; 133(2):714-8. PubMed ID: 6203975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of anti-Tac antibody on the response of large granular lymphocytes to interleukin-2.
    Mukaida N; Kasahara T; Hosoi J; Shioiri-Nakano K; Kawai T
    Immunology; 1986 Jan; 57(1):137-43. PubMed ID: 3002967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 2 and interferon-gamma are not sufficient to induce natural killer-like activity in human T cell clones.
    López-Botet M; Toribio ML; Moretta L; De Landázuri MO
    Eur J Immunol; 1984 Dec; 14(12):1137-41. PubMed ID: 6440795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.
    Braakman E; van Tunen A; Meager A; Lucas CJ
    Clin Exp Immunol; 1986 Nov; 66(2):285-94. PubMed ID: 2949897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells.
    Gerosa F; Tommasi M; Benati C; Gandini G; Libonati M; Tridente G; Carra G; Trinchieri G
    Cell Immunol; 1993 Sep; 150(2):382-90. PubMed ID: 8103709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    Lanier LL; Benike CJ; Phillips JH; Engleman EG
    J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
    Hafner M; Falk W; Echtenacher B; Männel DN
    Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells.
    Okabe M; Gomi K; Morimoto M; Nakamizo N
    Jpn J Cancer Res; 1985 Jul; 76(7):608-17. PubMed ID: 3928557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.